抗PD-1治疗失败后挽救性化疗获得完全缓解：观察与等待。 - Suppr

Suppr

超能文献

Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.

作者信息

Saleh Khalil, Bellanger Christophe, Garcia Gabriel, Classe Marion, Even Caroline

机构信息

Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Department of Gastroenterology, Hopital Kremlin Bicetre, Kremlin Bicetre, France.

出版信息

Eur J Cancer. 2021 Mar;145:155-157. doi: 10.1016/j.ejca.2020.12.020. Epub 2021 Jan 18.

DOI:10.1016/j.ejca.2020.12.020

PMID:33476895

Abstract

摘要

相似文献

Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.

Eur J Cancer. 2021 Mar;145:155-157. doi: 10.1016/j.ejca.2020.12.020. Epub 2021 Jan 18.

Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma.

Cancer Med. 2024 Jun;13(12):e7346. doi: 10.1002/cam4.7346.

Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.

Clin Transl Oncol. 2021 Sep;23(9):1961-1962. doi: 10.1007/s12094-021-02584-y. Epub 2021 Mar 17.

Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.

Dermatol Online J. 2020 Aug 15;26(8):13030/qt4c21b068.

Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer.

Int J Dermatol. 2020 Jun;59(6):685-686. doi: 10.1111/ijd.14742. Epub 2019 Nov 28.

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.

Front Immunol. 2020 Sep 18;11:1721. doi: 10.3389/fimmu.2020.01721. eCollection 2020.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.

Auris Nasus Larynx. 2020 Feb;47(1):116-122. doi: 10.1016/j.anl.2019.05.001. Epub 2019 May 23.

Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.

J Dermatol. 2019 May;46(5):e177-e178. doi: 10.1111/1346-8138.14684. Epub 2018 Oct 24.

Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.

Future Oncol. 2020 Dec;16(36):3035-3043. doi: 10.2217/fon-2020-0595. Epub 2020 Sep 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.

作者信息

Saleh Khalil, Bellanger Christophe, Garcia Gabriel, Classe Marion, Even Caroline

机构信息

Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Department of Gastroenterology, Hopital Kremlin Bicetre, Kremlin Bicetre, France.

出版信息

Eur J Cancer. 2021 Mar;145:155-157. doi: 10.1016/j.ejca.2020.12.020. Epub 2021 Jan 18.

DOI:10.1016/j.ejca.2020.12.020

PMID:33476895

Abstract

摘要

相似文献

Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.

Eur J Cancer. 2021 Mar;145:155-157. doi: 10.1016/j.ejca.2020.12.020. Epub 2021 Jan 18.

Obesity enhances the response to neoadjuvant anti-PD1 therapy in oral tongue squamous cell carcinoma.

Cancer Med. 2024 Jun;13(12):e7346. doi: 10.1002/cam4.7346.

Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.

Clin Transl Oncol. 2021 Sep;23(9):1961-1962. doi: 10.1007/s12094-021-02584-y. Epub 2021 Mar 17.

Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.

Dermatol Online J. 2020 Aug 15;26(8):13030/qt4c21b068.

Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer.

Int J Dermatol. 2020 Jun;59(6):685-686. doi: 10.1111/ijd.14742. Epub 2019 Nov 28.

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.

Front Immunol. 2020 Sep 18;11:1721. doi: 10.3389/fimmu.2020.01721. eCollection 2020.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.

Auris Nasus Larynx. 2020 Feb;47(1):116-122. doi: 10.1016/j.anl.2019.05.001. Epub 2019 May 23.

Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.

J Dermatol. 2019 May;46(5):e177-e178. doi: 10.1111/1346-8138.14684. Epub 2018 Oct 24.

Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.

Future Oncol. 2020 Dec;16(36):3035-3043. doi: 10.2217/fon-2020-0595. Epub 2020 Sep 9.